[1]林琪,张嘉颖,吴振,等.鞣花酸柔性纳米脂质体的制备工艺优化与体外透皮实验[J].华侨大学学报(自然科学版),2020,41(5):638-646.[doi:10.11830/ISSN.1000-5013.202001022]
　LIN Qi,ZHANG Jiaying,WU Zhen,et al.Preparation Optimization and In Vitro Percutaneous Permeability Experiment of Flexible Nanoliposomes of Ellagic Acid[J].Journal of Huaqiao University(Natural Science),2020,41(5):638-646.[doi:10.11830/ISSN.1000-5013.202001022]
点击复制

鞣花酸柔性纳米脂质体的制备工艺优化与体外透皮实验()
分享到：

《华侨大学学报（自然科学版）》[ISSN:1000-5013/CN:35-1079/N]

卷:
第41卷
期数:
2020年第5期
页码:
638-646
栏目:
出版日期:
2020-09-20

文章信息/Info

Title:
Preparation Optimization and In Vitro Percutaneous Permeability Experiment of Flexible Nanoliposomes of Ellagic Acid
文章编号:
1000-5013(2020)05-0638-09
作者:
林琪1;  张嘉颖1;  吴振2;  陈燕江3;  王立强1
1. 华侨大学 生物医学学院, 福建 泉州 362021;2. 厦门大学 药学院, 福建 厦门 361102;3. 晏容美业集团有限公司, 福建 厦门 361012
Author(s):
LIN Qi1;  ZHANG Jiaying1;  WU Zhen2;  CHEN Yanjiang3;  WANG Liqiang1
1. School of Biomedical Sciences, Huaqiao University, Quanzhou 362021, China; 2. Department of Pharmacy, Xiamen University, Xiamen 361102, China; 3. Yanrong Beauty Industry Group Limited Company, Xiamen 361012, China
关键词:
鞣花酸;  纳米;  柔性脂质体;  包封率;  体外透皮
Keywords:
ellagic acid;  nano;  flexible liposomes;  encapsulation efficiency;  in vitro percutaneous permeability
分类号:
R944.9
DOI:
10.11830/ISSN.1000-5013.202001022
文献标志码:
A
摘要:
以包封率为指标,考察鞣花酸柔性纳米脂质体(EA-FNL)的最佳制备工艺,验证其透皮效果.采用薄膜分散法制备鞣花酸柔性纳米脂质体,采用高效液相色谱法检测鞣花酸柔性纳米脂质体的包封率,通过单因素实验考察表面活性剂的种类、卵磷脂与表面活性剂的质量比、卵磷脂与胆固醇的质量比、药物质量浓度、水化时间对包封率和粒径的影响.经Box-Behnken效应面法得到最优处方,测定其粒径,以大鼠腹部皮肤为材料,进行24 h透皮扩散实验.结果表明:在Box-Behnken响应面优化处方实验确定的最佳工艺中,卵磷脂与胆固醇的质量比为7.83∶1,脂质体制备水化时间为2.1 h,卵磷脂与吐温-20的质量比为2∶1,平均包封率为75.66%,粒径为(178.60±4.59)nm,聚合物分散性指数(PDI)为0.15±0.01,电位为(-30.60±0.92)mV,EA-FNL稳定性良好;EA-FNL 24 h累积透过量为9.54 μg·cm-2,24 h后皮肤滞留量为13.77 μg·cm-2;文中方法制备的鞣花酸柔性纳米脂质体包封率较高,粒径可控,在皮肤滞留量较高.
Abstract:
The optimum preparation technology of flexible nanoliposomes of ellagic acid(EA-FNL)was studied with encapsulation efficiency as index, and its transdermal effect was verified. EA-FNL was prepared by thin film dispersion, and the encapsulation efficiency of EA-FNL was determined by high performance liquid chromatography. The effects of the type of surfactant, the mass ratio of lecithin and surfactant, the mass ratio of lecithin and cholesterol, the concentration of medicine, and the hydration time on the encapsulation efficiency and the particle size were investigated by single factor test. The optimal prescription was obtained by theBox-Behnken response surface method, and the particle size was measured. A 24 h transdermal diffusion experiment was performed using rat abdominal skin as a material. The result shows that optimal prescription was: a mass ratio of lecithin to cholesterol 7.83∶1, the hydration time for liposome preparation 2.1 h, and the mass ratio of lecithin to Tween-20 2∶1. Under the optimal prescrition, the average encapsulation efficiency was 75.66%, particle size was(178.60±4.59)nm, the polymer dispersity index(PDI)was 0.15±0.01, the potential was(-30.60±0.92)mV, and the stability of EA-FNL was good. The cumulative transmittance of EA-FNL for 24 h was 9.54 μg·cm-2, and the skin retention at 24 h was 13.77 μg·cm-2. It reveals that EA-FNL prepared by this method has higher encapsulation efficiency, controllable particle size and high retention in skin.

参考文献/References:

[1] BACCARIN T,LEMOS-SENNA E.Potential application of nanoemulsions for skin delivery of pomegranate peel polyphenols[J].AAPS Pharm Sci Tech,2017,18(8):3307-3314.DOI:10.1208/s12249-017-0818-x.
[2] ZEB A.Ellagic acid in suppressing in vivo and in vitro oxidative stresses[J].Molecular and Cellular Biochemistry,2018,448(1/2):27-41.
[3] KUBA-MIYARA M,AGARIE K,SAKIMA R,et al.Inhibitory effects of an ellagic acid glucoside, okicamelliaside, on antigen-mediated degranulation in rat basophilic leukemia RBL-2H3 cells and passive cutaneous anaphylaxis reaction in mice[J].Int Immunopharmacol,2012,12(4):675-681.DOI:10.1016/j.intimp.2012.01.013.
[4] BENSAAD L,KIM K H,QUAH T C C,et al.Anti-inflammatory potential of ellagic acid, gallic acid and punicalagin A & B isolated from punicagranatum[J].BMC Complement Altern Med,2017,17(1):47-57.DOI:10.1186/s12906-017-1555-0.
[5] 韩奇亨,张春红,龚雪,等.鞣花酸类化合物在野牡丹科植物中的分布与药理活性研究[J].中药材,2018,41(12):2962-2967.
[6] LIM S C,HWANG H,HAN S L.Ellagic acid inhibits extracellular acidity-induced invasiveness and expression of COX1, COX2, snail, twist 1, and c-myc in gastric carcinoma cells[J].Nutrients,2019,11(12):3023.DOI:10.33 90/nu11123023.
[7] ZAAZAA A,LOKMAN M S,SHALBY A B,et al.Ellagic acid holds promise against hepatocellular carcinoma in an experimental model: Mechanisms of action[J].Asian Pac J Cancer Prev,2018,19(2):387-393.DOI:10.22034/APJCP.2018.19.2.387.
[8] DEROSA G,MAFFIOLI P,SAHEBKAR A.Ellagic acid and its role in chronic diseases[J].Adv Exp Med Biol,2016,928:473-479.DOI:10.1007/978-3-319-41334-1_20.
[9] ORTIZ-RUIZ C V,BERNA J,TUDELA J,et al.Action of ellagic acid on the melanin biosynthesis pathway[J].J Dermatol Sci,2016,82(2):115-122.DOI:10.1016/j.jdermsci.2016.02.004.
[10] WANG Yi,ZENG Yang,FU Wensheng,et al.Seed-mediated growth of Au@Ag core-shell nanorods for the detection of ellagic acid in whitening cosmetics[J].Anal Chim Acta,2018,1002:97-104.DOI:10.1016/j.aca.2017.11.067.
[11] PANICHAYUPAKARANANT P,ITSURIYA A,SIRIKATITHAM A.Preparation method and stability of ellagic acid-rich pomegranate fruit peel extract[J].Pharm Biol,2010,48(2):201-205.DOI:10.3109/13880200903078503.
[12] MO J,KAEWNOPPARAT N,SONGKRO S,et al.Physicochemical properties, in vitro release and skin permeation studies of a topical formulation of standardized pomegranate rind extract[J].Pak J Pharm Sci,2015,28(1):29-36.
[13] JIANG Tianyue,WANG Tong,LI Teng,et al.Enhanced transdermal drug delivery by transfersome-embedded oligopeptide hydrogel for topical chemotherapy of melanoma[J].ACS Nano,2018,12(10):9693-9701.DOI:10.1021/acsnano.8b03800.
[14] 刘基,王媚,王露,等.经皮给药系统研究进展[J].现代中医药,2018,38(6):156-159.
[15] HAO Ying,LI Wei,ZHOU Xingli,et al.Microneedles-based transdermal drug delivery systems: A review[J].J Biomed Nanotechnol,2017,13(12):1581-1597.DOI:10.1166/jbn.2017.2474.
[16] 陈桐楷,林华庆,李园.柔性纳米脂质体经皮给药新载体的研究进展[J].中国药师,2009,12(6):732-734.
[17] LI Chong,ZHANG Xiaolin,HUANG Xinliang,et al.Preparation and characterization of flexible nanoliposomes loaded with daptomycin, a novel antibiotic, for topical skin therapy[J].International Journal of Nanomedicine,2013,8:1285-1292.DOI:10.2147/IJN.S41695.
[18] 陈华兵.促进药物透皮和皮肤靶向的纳米载药系统研究[D].武汉:华中科技大学,2008.
[19] KUMAR A,PATHAK K,BALI V.Ultra-adaptable nanovesicular systems: A carrier for systemic delivery of therapeutic agents[J].Drug Discov Today,2012,17(21/22):1233-1241.DOI:10.1016/j.drudis.2012.06.013.
[20] BNYAN R,KHAN I,EHTEZAZI T,et al.Surfactant effects on lipid-based vesicles properties[J].Journal of Pharmaceutical Sciences,2018,107(5):1237-1246.DOI:10.1016/j.xphs.2018.01.005.
[21] 孙盟璐.薄膜法中胆固醇的比例对维生素C脂质体性质的影响[J].现代化农业,2017(8):41-42.
[22] 刘广,齐娜,孙考祥,等.延胡索乙素柔性脂质体的制备与透皮吸收[J].中国实验方剂学杂志,2013,19(8):37-39.
[23] 刘剑敏,唐静宜,程路,等.正交设计优化磷酸川芎嗪-冰片脂质体的制备工艺[J].中国药业,2019,28(11):44-47.
[24] KULKARNI S B,SINGH M,BETAGERI G V.Encapsulation, stability and in-vitro liposomal formulations release characteristics of colchicine[J].Journal of Pharmacy and Pharmacology,1997,49(5):491-495.DOI:10.1111/j.2042-7158.1997.tb06829.x.
[25] 张小滨,侯新朴.不同表面活性剂对伊文思蓝脂质体体内外性质的影响[J].中国药物与临床,2003(1):5-8.
[26] GONZáLEZ-RODRíGUEZ M L,BARROS L B,PALMA J,et al.Application of statistical experimental design to study the formulation variables influencing the coating process of lidocaine liposomes[J].Int J Pharm,2007,337(1/2):336-345.DOI:10.1016/j.ijpharm.2007.01.024.
[27] FANG Zhao,JIA Lu,XIN Jin,et al.Comparison of response surface methodology and artificial neural network to optimize novel ophthalmic flexible nano-liposomes: Characterization, evaluation, in vivo pharmacokinetics and molecular dynamics simulation[J].Colloids Surf B Biointerfaces,2018,172:288-297.DOI:10.1016/j.colsurfb.2018.08.046.

相似文献/References:

[1]张煌博,曹学功,孙向英.碳点的制备及其荧光共振能量转移[J].华侨大学学报(自然科学版),2014,35(6):680.[doi:10.11830/ISSN.1000-5013.2014.06.0680]
　ZHANG Huang-bo,CAO Xue-gong,SUN Xiang-ying.Preparation and Fluorescence Resonance Energy Transfer of Carbon Dots[J].Journal of Huaqiao University(Natural Science),2014,35(5):680.[doi:10.11830/ISSN.1000-5013.2014.06.0680]

备注/Memo

备注/Memo:
收稿日期: 2020-01-18
通信作者: 王立强(1970-),男,教授,博士,主要从事药剂学和创新药物的研究.E-mail:wlq1599@163.com.
基金项目: 国家重点研发计划项目(2016YFE0101700); 福建省高校产学合作项目(2019Y4007); 华侨大学研究生科研创新基金资助项目(18013071019)http://www.hdxb.hqu.edu.cn
更新日期/Last Update: 2020-09-20